Delanzomib

Drug Profile

Delanzomib

Alternative Names: CEP-18770; CIP 18770; CT-18770; CT-47098; E/CEP-18770; NP-47098; NPH007098

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cephalon
  • Developer Cephalon; EOS S.p.A.; Teva Pharmaceutical Industries
  • Class Amino acids peptides and proteins; Antineoplastics; Boronic acids; Peptidomimetics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Non-Hodgkin's lymphoma; Solid tumours; Systemic lupus erythematosus
  • Discontinued Multiple myeloma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma in Italy (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma in Switzerland (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Italy (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top